PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449A/B/P1	го		Complete if Known		
				Application Number	10/671,715-Conf. #9275	
11	IFORMATION	N DI	SCLOSURE	Filing Date	September 29, 2003	
S	TATEMENT I	BY /	APPLICANT	First Named Inventor	Harry A. Dugger III	
				Art Unit	1616	
	(Use as many sheets as necessary)			Examiner Name	Mina Haghighatian	
Sheet	2	of	3	Attorney Docket Number	N9810.0025/P025	

	A41	US 2006/222,597	10-2006	Dugger et al.	\neg
}	A42	US 2007/048,229	03-2007	Dugger et al.	
	A43	US 4,495,168	01-1985	Schmolka	
1	A44		11-1987		
		US 4,704,406		Stanislaus et al.	
-	A45	US 4,814,161	03-1989	Jinks et al.	
	A46	US 4,863,720	09-1989	Burghart et al.	_
	A47	US 4,863,970	09-1989	Patel et al.	
	A48	US 5,143,731	09-1992	Viegas et al.	_
	A49	US 5,166,145	11-1992	Francisco Jao, et al.	
L	A50	US 5,290,540	03-1994	Prince et al.	
<u> </u>	A51	US 5,502,076	03-1996	Dixit et al.	\Box
	A52	US-5,519,059	05-1996	Sawaya	
	A53	US-5,593,684	01-1997	Kramer	
	A54	US 5,602,182	02-1997	Popli et al.	
ļ	A55	US 5,605,674	02-1997	Purewal et al.	\neg
	A56	US 5,607,915	03-1997	Patton	\neg
	A57	US 5,635,161	06-1997	Adjei et al.	
	A58	US 5,645,856	07-1997	Lacy et al.	
	A59	US 5,725,841	03-1998	Duan et al.	
	A60	US 5,795,909	08-1998	Shashoua et al.	
	A61	US 5,824,307	10-1998	Johnson	\neg
	A62	US 5,891,465	04-1999	Keller et al.	\neg
	A63	US 5,906,811	05-1999	Hersch, Theodore	
	A64	US 5,908,611	06-1999	Gottlieb et al.	\neg
	A65	US-6,110,486	08-2000	Dugger III	\neg
	A66*	US 6,143,329	11-2000	Kim, Soo-II	\neg
_	A67	US 6,212,227	04-2001	Ko et al.	$\neg \uparrow$
	A68	US 6,258,032	07-2001	Hammesfahr	\neg
	A69	US 6,299,900	10-2001	Reed et al.	\neg
	A70	US 6,375,975	04-2002	Modi	コ
	A71	US 6,512,002	01-2003	Lee et al.	\neg
-	A72	US 6,676,931	01-2004	Dugger	\neg
	A73	US 6,816,452	11-2004	Machata	\neg
	A74	US 6,969,508	11-2005	Dugger, III, Harry A.	\neg
	A75	US 6,977,070	12-2005	Dugger, III, Harry A.	\neg
	A76	US 6,998,110	02-2006	Dugger, III, Harry A.	一
	A77	US 7,202,233	04-2007	Penkler	\neg
				<u> </u>	

		FOREIG	N PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	B01	EP 0386700	09/1990			
	B02	GB 2295318	05/1996			
Examine Signature	-			Date Considered		

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/671,715-Conf. #9275	
l ir	NFORMATIO	N DISC	LOSURE	Filing Date	September 29, 2003	
S	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Harry A. Dugger III	
				Art Unit	1616	
				Examiner Name	Mina Haghighatian	
Sheet	3	of	3	Attorney Docket Number	N9810.0025/P025	

B03	IE 912509 A1	02/1992	
B04	WO 00/06534	02/2000	
B05	WO 00/27359	05/2000	
B06	WO 02/066089	08/2002	
B07	WO 02/43695	11/2001	
B08	WO 95/31217	11/1995	
B09	WO 98/29097	07/1998	
B10	WO 98/52540	11/1998	
B11	WO 98/52545	11/1998	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹						
	C01	Drug Facts and Comparisons (Jan. 2002) pp. 186c-186d					
	C02	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., (1996), pp. 141-154, 169-170, 260, 303-304, 324, 362, 372, 420-422, 427, 471, 472, 478-480, 484, 490, 496-497, 928-930					
	C03	KARLSSON, et al.; "A Comparison of the Effect of Inhaled Diuretics on Airway Reflexes in Humans and Guinea Pigs", <i>The American Physiological Society</i> , pp. 434-438 (1992)					
	C04	L.W. BROX, et al.; "Studies on the Growth Inhibition and Metabolism of 2'-Deoxy-2' fluorocytidine in Cultured Human Lymphoblasts"; Cancer Research, Vol. 34, pp 1838-1842 (1974)					
	C05	Maarek et al., "The Safety and Efficacy of Zolpidem in Insomniac Patients: a Long-Term Open Study in General Practice," J. Int. Med. Res., 1992, 2092), 162-170.					
	C06	MOCHIZUKI, et al.; Inhaled Diuretics Attenuate Acid-Induced Cough in Children With Asthma"; Chest, 107/2 pp. 413-417 (1995)					
	C07	Physician's Desk Reference, 1995, pp 858-861, 2436-2441, 2548-2550					
	C08	Schlich, D., et al., "Long-terma treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients." The Journal of International Medical Research, 1991, 19(3), pp. 271-279.					
	C09	TING-CHAO CHOU, et al.; "Pharmacological Disposition and Metabolic Fate of 2'-Fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in Mice and Rats"; Cancer Research, Vol. 41, pp 3336-3342 (1981)					
	C10	WOODLEY et al., Manual of Medical Therapeutics, 27th Edition, 1992, pp 341 and 370-371					
	C11	Written Opinion of the International Searching Authority – 2/28/06					
	C12	YE, JIANG HONG et al.; "Ondansetron Exhibits The Properties of a Local Anesthetic"; Anesthesia and Analgesia, Vol. 85. No. 5, November 1997; pgs 1116-1121					
	C13	ZERVAKIS, et al.; "Taste Effects of Lingual Application of Cardiovascular Medications"; Physiology & Behavior, 68: pp. 405-413 (2000)					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
	Date
Signature	Canaidarad
Olghaldie 1	Considered